The global sickle cell anemia testing and screening market is projected to grow from USD 1.7 billion in 2025 to USD 3.6 billion by 2033, driven by rising disease prevalence and expanding public health initiatives. With a CAGR of 9.8%, the market reflects urgent demand for early diagnosis, especially in high-burden regions like sub-Saharan Africa, India, and the Middle East.

For a deeper dive into market segmentation and forecasts, check out the full report on https://m2squareconsultancy.com/reports/sickle-cell-anemia-testing-and-screening-market

Hemoglobin electrophoresis remains the dominant testing method, accounting for 43.2% of the market, followed by HPLC and point-of-care diagnostics. Newborn screening leads age-group segmentation, supported by government mandates and global health programs aimed at reducing infant mortality.

Government laboratories play a pivotal role, backed by funding from WHO, the Gates Foundation, and regional health ministries. Public-private partnerships are also accelerating access to diagnostics in underserved areas.

Technological advancements—such as AI-powered tools and portable testing devices—are reshaping accessibility and accuracy. Meanwhile, genetic testing is gaining ground for prenatal screening.

As awareness grows and infrastructure improves, the market is poised for sustained expansion. Stakeholders across healthcare, diagnostics, and policy must align to ensure equitable access and early intervention.

Get More Links :

https://m2squareconsultancy.com/reports/urine-testing-cups-market

https://m2squareconsultancy.com/reports/global-vaccines-market

https://m2squareconsultancy.com/reports/surgical-instruments-market

https://m2squareconsultancy.com/reports/predictive-analytics-market

https://m2squareconsultancy.com/reports/smart-cities-market

https://m2squareconsultancy.com/reports/seed-treatment-market